TirzepatidePhysician guide Find a briefing ↓

Care · After the decision

Who answers after the first visit?

Ask how the conversation continues

The Food and Drug Administration (FDA) flags remote care when, after delivery, a licensed doctor is unavailable to answer questions.

Find out where questions go, who will read yours, and how long a response should take. Ask what to do when the question cannot wait for that reply.

Get the urgent-care instructions before you need them. Keep the service’s instructions where you can find them without signing in again.

Separate refills from follow-up

Ask what must happen before a refill. Will someone review how treatment is going? Who takes over if the person treating you is unavailable?

Ask how to get your records if you change care settings. Ask whether access to messages stops when a membership ends. These are useful questions even when the first visit is covered.

Discuss a change of plan

In the SURMOUNT-4 trial, people who switched from tirzepatide to a placebo regained weight on average.

A placebo contains no active drug. Ask how that study fits the longer plan being proposed for you.

Ask how the person treating you would handle treatment that does not suit you, an insurance change, or a decision to stop. Ask what care remains available in each case.

Check the medicine when it arrives

FDA flags damaged packaging, missing instructions, and suspicious pharmacy details as reasons for concern.

Ask in advance who handles a delivery or label problem. A delivery tracker does not answer a medicine question.

Read the label cautions and urgent-help signs →